LoE: loss of exclusivity
Loss of exclusivity (LoE) is the date when the last regulatory or patent protection on a medicine ends and generics or biosimilars can be marketed.
Loss of exclusivity is a planning term rather than a legal one. It names the point at which no layer of protection prevents a competitor from placing a generic, hybrid or biosimilar version on the market in a given country. The layers come from different laws: regulatory data protection and market protection under Article 10(1) of Directive 2001/83/EC and Article 14(11) of Regulation (EC) No 726/2004; the basic patent and any supplementary protection certificate under Regulation (EC) No 469/2009; the six-month paediatric extension of the certificate under Regulation (EC) No 1901/2006; and, for orphan medicines, the ten-year market exclusivity under Regulation (EC) No 141/2000. The LoE date is the latest of those that applies, and it can differ by Member State because patents and certificates are national and because orphan exclusivity and market protection are EU-wide.
Working it out means answering several questions in order. When was the reference product first authorised in the EU, which fixes the 8+2+1 periods? Did a new indication earn the extra year of market protection? Which patents are in force in which countries, and which have certificates? Was a paediatric investigation plan completed and the extension granted? For an orphan product, has the exclusivity been shortened or extended, and does it apply to all indications? The answer is a table by country, and it changes when litigation invalidates a patent, when a certificate is granted late, or when an orphan designation is withdrawn.
For a generic developer the same analysis sets the earliest filing date (end of data protection) and the earliest launch date (end of market protection, patents and certificates). Development can begin before filing under the Bolar exemption, and stock can be built in the last six months of a certificate under the SPC manufacturing waiver.
What goes wrong: forecasts use a single global date for a product that loses protection on different dates in different countries; market protection is counted from a national approval instead of the first EU authorisation; a late-granted certificate or a paediatric extension is missed; a patent still pending is ignored; and nobody tracks that a generic has been authorised but not launched, which is the signal that the originator's date is near.
Under the new pharma package (not yet in force), baseline market protection for reference products filed after the new rules apply falls from two years to one, with conditional extensions up to eleven years in total, so LoE dates for those products will depend on which conditions were met; see exclusivity changes.
Used in
Portfolio and launch teams document each protection layer and the resulting entry date per market in the loss-of-exclusivity workflow.
Related terms
- Data exclusivity: regulatory data protectionData exclusivity is the eight years after a reference product's first EU authorisation in which generics cannot rely on its preclinical and clinical data.
- Market protection: period in which generics cannot be marketedMarket protection is the period after data exclusivity ends during which a generic or biosimilar can be authorised but not placed on the market.
- SPC: supplementary protection certificateA supplementary protection certificate (SPC) extends patent protection for an authorised medicine by up to five years to offset regulatory review time.
- Paediatric extension: six-month SPC extension for a completed PIPThe paediatric extension adds six months to a supplementary protection certificate as a reward for completing an agreed paediatric investigation plan.
- Orphan market exclusivity: ten-year protection for orphan medicinesOrphan market exclusivity gives an authorised orphan medicine ten years in which no similar product may be authorised for the same therapeutic indication.
Last updated